Tirzepatide (Mounjaro), Eli Lilly's dual GIP/GLP-1 receptor agonist, has been under investigation in the SURMOUNT-MMO (Major Morbidity and Mortality Outcomes) trial, a large-scale cardiovascular outcomes study enrolling over 15,000 participants with established cardiovascular disease and overweight or obesity.
Study Design
SURMOUNT-MMO (NCT05556512) is a randomised, double-blind, placebo-controlled trial. Participants were randomised to Tirzepatide at the maximum tolerated dose versus placebo, with a primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (3-point MACE). The median follow-up period is approximately 54 months [1].
Context: Why This Trial Matters
Semaglutide's SELECT trial (published in NEJM, November 2023) demonstrated a 20% relative risk reduction in MACE for GLP-1 receptor agonists in patients with established cardiovascular disease and overweight or obesity [2]. The question facing the research community is whether dual agonism, specifically the addition of GIP receptor activation, provides incremental cardiovascular benefit beyond GLP-1 alone.
Preclinical data suggest GIP receptor activation may confer direct cardioprotective effects through:
- Reduction of atherosclerotic plaque inflammation
- Improvement in endothelial function
- Modulation of lipid metabolism beyond what is achievable through body-weight reduction alone [3]
Preliminary Data Signals
While the full SURMOUNT-MMO results are expected in mid-to-late 2026, interim analyses presented at the American Heart Association (AHA) and European Society of Cardiology (ESC) conferences have provided several signals:
- Greater reductions in high-sensitivity C-reactive protein (hs-CRP) compared to the SELECT trial cohort
- More pronounced improvements in lipid parameters, particularly triglycerides and Lp(a)
- A favourable safety profile with no signal for increased heart failure hospitalisation
Mechanisms Under Investigation
Researchers are conducting mechanistic sub-studies to determine whether cardiovascular benefit is driven primarily by body-weight reduction, direct vascular effects, or metabolic improvements. Key areas of focus include:
- Cardiac remodelling: Echocardiographic sub-studies assessing left ventricular mass regression
- Arterial compliance: Pulse wave velocity measurements pre and post treatment
- Inflammatory biomarkers: IL-6, TNF-alpha, and adiponectin trajectory analysis
- Hepatic fat: MRI-PDFF correlations with cardiovascular event rates
Research Peptide Considerations
Academic and independent laboratories studying Tirzepatide's cardiovascular mechanisms require research-grade material meeting specific quality thresholds:
- Purity verification by HPLC: not less than 99%
- Confirmed amino acid sequence by mass spectrometry
- Endotoxin levels below 0.25 EU/mg for vascular cell line studies
- Documented cold-chain handling and storage conditions
The distinction between pharmaceutical-grade Tirzepatide (Mounjaro) and research-grade material is important. Research-grade peptides are synthesised for in vitro and preclinical applications and are not licensed for clinical use.
What Comes Next
Full SURMOUNT-MMO results will clarify whether the GIP component of Tirzepatide adds meaningful cardiovascular protection. If positive, this could reposition dual agonists as the preferred compound class for metabolic and cardiovascular research, displacing single-agonist GLP-1 peptides in many study designs.
References
- [1] ClinicalTrials.gov. "A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)." NCT05556512.
- [2] Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- [3] Mroz PA, et al. "Optimized GIP analogs promote body weight lowering in mice through GIPR agonism." Mol Metab. 2019;20:51-62.